Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...

Four Mexican pharmaceutical companies have announced plans to invest more than 13 billion pesos in drug development and ...

The analysis reveals a strong dominance of AI applications in oncology, comprising 72.8% of all included studies. This skew ...

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives. Springer; 2021 pp 147-160. Woodcock J & LaVange LM.

The forward-looking statements include statements regarding maximizing efficiency, cost-effectiveness, and the likelihood of success of Adial’s upcoming trial, enabling a refined Phase 3 ...

China’s pharmaceutical innovation ecosystem has matured rapidly, positioning the country as a hub for cutting-edge drug development and a valuable source of research. A major factor in this growth is ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

From the Analyst's Couch Published: October 2009 Psoriasis market Irena Melnikova Nature Reviews Drug Discovery 8, 767–768 (2009) Cite this article ...

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin ...